The aim of this contribution was to compare the effectivness of a plasmid encoding canine IL-12 with gene for kanamicin resistance to plasmid encoding human IL-12 with a gene for ampicilin resistance in in vitro and in vivo conditions after gene electrotransfer of human and canine cell lines. So far, plasmid encoding human IL-12 has been used in clinical studies on dogs. For more specific treatment there is a need for a plasmid encoding canine IL-12. Also, new plasmid has a resistance for kanamicin which is allowed by the regulatory agencies for use in clinical studies. Our results showed that there was no statistical significant difference between both plasmid on expression level of mRNA and proteins. Also, we showed that both plasmids had comparable therapeutic effect on canine tumor cells CMeC-1 after gene electrotransfer in invivo conditions on nude mice. In the scope of this research we showed that new plasmid encoding canine IL-12 is suitable for further clinical studies on dogs. Award: The contribution was awarded with 3. place in Young Investigator Competition
B.03 Paper at an international scientific conference
COBISS.SI-ID: 2103163Prof. Maja Čemažar held lectures at two foreign universities in Belgium. At the Universiteit Gent she presented the results of preclinical studies and clinical trials in veterinary oncology on interleukin-12 gene therapy alone or in combination with electrochemotherapy. Additionally, prof. Cemazar was one of the defence comitee of Sofie Denies PhD thesis entitled: ˝Cancer Immunotherapy: Tumor vaccination, IL-12 gene therapy and metronomic chemotherapy˝.
B.05 Guest lecturer at an institute/university
COBISS.SI-ID: 2184827Prof. Maja Čemažar was a supervisor of PhD thesis of young researcher Nataša Tešić. In 2015, Nataša Tešić successfully defended her PhD thesis entitled Preparation and validation of therapeutic plasmids without gene for antibiotic resistance and with tissue specific promoters for cancer gene therapy.
D.09 Tutoring for postgraduate students
COBISS.SI-ID: 279631616